^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ADI-002

    i
    Other names: ADI-002, 41BBζ-sIL15 GPC3-CAR Vδ1 T cell therapy, GPC-3.sIL-15.CAR Vδ1 T cells, ADI 002, ADI002
    Associations

    News

    Trials
    Company:
    Adicet Bio, Regeneron
    Drug class:
    γδ TCR modulator, IL-15R agonist, GPC-3-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    3years
    ADI-002: an IL-15 armored allogeneic “off-the-shelf” Vδ1 gamma delta CAR T cell therapy for solid tumors targeting glypican-3 (GPC3) (SITC 2021)
    When compared to GPC-3.CAR Vδ1 T cells lacking sIL-15, GPC-3.sIL-15.CAR Vδ1 T cells displayed greater tumor-specific proliferation that resulted in enhanced tumor control (figure 1). Conclusions Expanded Vδ1 T cells engineered with GPC-3.CAR and sIL-15 represent a promising approach for safe and effective off-the-shelf treatment of HCC and support further investigation in the clinical setting.
    CAR T-Cell Therapy • IO biomarker
    |
    KEAP1 (Kelch Like ECH Associated Protein 1) • GPC3 (Glypican 3) • CD27 (CD27 Molecule)
    |
    ADI-002
    over3years
    [VIRTUAL] Allogeneic Vδ1 gamma delta T cells engineered with glypican-3 (GPC3)-specific CAR expressing soluble IL-15 have enhanced antitumor efficacy against hepatocellular carcinoma in preclinical models. (ASCO 2021)
    Our results show that expanded Vδ1 T cells engineered with GPC3-CAR and sIL-15 represent a promising platform for safe and effective off-the-shelf treatment of HCC.
    Preclinical • IO biomarker
    |
    GPC3 (Glypican 3) • CD27 (CD27 Molecule)
    |
    ADI-002